Future investigations into the source of this shift - whether differences in O-GlcNAc levels, OGT/OGA targeting, or the larger O-GlcNAc interactome – may prove fruitful in delineating and abrogating the self-sustaining pathways between progressive obesity and metabolic disease. The gene discussed is OGA; the disease is obesity disorder.